Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supernus PharmaceuticalsLTS:0LB2 +0.17%88 Cyclically Adjusted PS Ratio is 4.59 as of Jul. 14, 2026, which is 4% below its 10-year median of 4.80. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $41.44 (Modestly Overvalued). Among 752 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 74.2% on this metric.
The historical rank and industry rank for Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
LTS:0LB2'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.92 Med: 4.8 Max: 7.34
Current: 4.31
During the past years, Supernus Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 7.34. The lowest was 2.92. And the median was 4.80.
LTS:0LB2's Cyclically Adjusted PS Ratio is ranked worse than 74.2% of 752
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs LTS:0LB2: 4.31
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Supernus Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2026 was $3.603. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $10.47 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Supernus Pharmaceuticals (LTS:0LB2) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms
Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Chart
LTS:0LB2 vs BCRX, PBH, RGC: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 4.59 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Cyclically Adjusted PS Ratio of 4.59 as of Jul. 14, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. This is near median its historical median of 4.80. Over the past decade, Supernus Pharmaceuticals' Cyclically Adjusted PS Ratio has ranged from 2.92 to 7.34. According to the industry distribution chart, Supernus Pharmaceuticals ranks #558 out of 752 companies in the Drug Manufacturers industry, placing it in the top 74.2%.
Is Supernus Pharmaceuticals' Cyclically Adjusted PS Ratio too high?
Supernus Pharmaceuticals' current Cyclically Adjusted PS Ratio of 4.59 is near median its 10-year median of 4.80. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 7.34. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 1.99. Supernus Pharmaceuticals' value of 4.59 is 130.7% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #558 out of 752 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Cyclically Adjusted PS Ratio compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #558 out of 752 companies for Cyclically Adjusted PS Ratio. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.99. Supernus Pharmaceuticals' value of 4.59 is 130.7% above this benchmark. Historically, Supernus Pharmaceuticals' own Cyclically Adjusted PS Ratio has ranged from 2.92 to 7.34 over the past decade. While the company's 10-year median is 4.80 vs. the industry median of 1.99, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 1.99, based on 752 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Cyclically Adjusted PS Ratio of 4.59 is 130.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Cyclically Adjusted PS Ratio is 4.59, which is near median its own 10-year median of 4.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $41.44, compared to a current price of $48.03 — trading 15.9% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 4.59, which is near median its 10-year median of 4.80 and 130.7% above the Drug Manufacturers industry median of 1.99. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Cyclically Adjusted PS Ratio is 4.59 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $48.03 is trading 15.9% above its estimated GF Value™ of $41.44.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Cyclically Adjusted PS Ratio: 4.59 (near median its 10-year median of 4.80)
GF Value™: $41.44 vs. price of $48.03 (15.9% above fair value)
Industry Position: 130.7% above the Drug Manufacturers median (#558 of 752)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
